Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT03618550
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- NCT03618550 ↗
- Recruiting
- Memorial Sloan Kettering Cancer Center
- Focused
We haven't built an HCP commentary report on NCT03618550 (pembrolizumab plus GVD in relapsed or refractory classical Hodgkin lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03618550 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Hodgkin Lymphoma; Relapsed or Refractory Hodgkin Lymphoma
- Interventions
- pembrolizumab; gemcitabine; vinorelbine; liposomal doxorubicin; Stem cell mobilization and collection; Involved-site radiation therapy
- Arms
- Safety Window and DLT definition (Part 1) · Experimental
- Safety monitoring beyond after completion of safety window (PART 1) · Experimental
- Autologous Stem Cell Transplant (ASCT) (PARTS 1 and 3) · Experimental
- Pembrolizumab maintenance (PART 2) · Experimental
- Pembrolizumab maintenance, third-line therapy, and HDT/ASCT (PART 3A) · Experimental
- Involved-site radiation therapy (ISRT) (PART 3B) · Experimental
- Enrollment
- 257 (estimated)
- Primary outcomes
- Complete response rate (part 1)
- Assess freedom from disease at 5 years (part 3)
- Sponsor
- Memorial Sloan Kettering Cancer Center with Merck Sharp & Dohme LLC
- Start
- Aug 1, 2018
- Primary completion
- Aug 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03618550 · updated Oct 23, 2026
Publications
linked from the registry- Moskowitz AJ, Shah G, Schoder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25. PubMed 34170745
- Ma S, Spinner MA. Optimizing the Role of Checkpoint Inhibitors in the Management of Hodgkin Lymphoma. J Natl Compr Canc Netw. 2026 Feb;24(2):e257125. doi: 10.6004/jnccn.2025.7125. PubMed 41698326